Oral bisphosphonates and the risk of Barrett's esophagus: Case-control analysis of US veterans

American Journal of Gastroenterology

Volumn 108, Issue 10, 2013, Pages 1576-1583

  Lin, Derek ^a   Kramer, Jennifer R ^a   Ramsey, David ^a   Alsarraj, Abeer ^a   Verstovsek, Gordana ^a,b   Rugge, Massimo ^c   Parente, Paola ^d   Graham, David Y ^a,b   El Serag, Hashem B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; RISEDRONIC ACID;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; COLONOSCOPY; CONTROLLED STUDY; DRUG USE; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RACE; RISK FACTOR; SEX; UNITED STATES; VETERAN; WAIST HIP RATIO;

AGED; ALENDRONATE; BARRETT ESOPHAGUS; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DIPHOSPHONATES; ENDOSCOPY, DIGESTIVE SYSTEM; ETIDRONIC ACID; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HERNIA, HIATAL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OSTEOPOROSIS; PROTON PUMP INHIBITORS; RISK FACTORS; UNITED STATES; VETERANS; WAIST-HIP RATIO;

EID: 84885478752     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.222     Document Type: Article

References (30)

1. Udell JA, Fischer MA, Brookhart MA et al. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006; 21: 765-71
2. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profi les of bisphosphonates. Dig Dis Sci 2002; 47: 1665-78
3. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: An endoscopic study. Gastroenterology 2005; 129: 1825-31
4. Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988; 19: 942-8
5. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003; 27: 999-1008
6. Wysowski DK. Oral bisphosphonates and oesophageal cancer. BMJ 2010; 341: C4506
7. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 89-90
8. Green J, Czanner G, Reeves G et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 2010; 341: C4444
9. Cardwell CR, Abnet CC, Cantwell MM et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-63
10. Ho YF, Lin JT, Wu CY. Oral bisphosphonates and risk of esophageal cancer: A dose-intensity analysis in a nationwide population. Cancer Epidemiol Biomarkers Prev 2012; 21: 993-5
11. Abrahamsen B, Pazianas M, Eiken P et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012; 27: 679-86
12. Kramer JR, Fischbach LA, Richardson P et al. Waist to hip ratio but not body mass index is associated with increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol 2013; 11: 373
13. Olliver JR, Hardie LJ, Gong Y et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14: 620-5
14. Colleypriest BJ, Ward SG, Tosh D. How does Inflammation cause Barrett's metaplasia? Curr Opin Pharmacol 2009; 9: 721-6
15. Chen H, Fang Y, Tevebaugh W et al. Molecular mechanisms of Barrett's esophagus. Dig Dis Sci 2011; 56: 3405-20
16. Ribeiro A, DeVault KR, Wolfe JT III et al. Alendronate-associated esophagitis: Endoscopic and pathologic features. Gastrointest Endosc 1998; 47: 525-8
17. Rogers MJ, Crockett JC, Coxon FP et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49: 34-41
18. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59: 193-202
19. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal refl ux disease. Gastroenterology 2008; 135: 1383-91
20. Thrift AP, Pandeya N, Smith KJ et al. The use of nonsteroidal antiInflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011; 34: 1235-44
21. Anderson LA, Johnston BT, Watson RG et al. Nonsteroidal anti-Inflammatory drugs and the esophageal Inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006; 66: 4975-82
22. US Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. September 2011 Available at http://www.nice.org. uk/media/91D/04/MedicinesAwarenessWeekly310812.pdf
23. Blank MA, Ems BL, Gibson GW et al. Nonclinical model for assessing gastric Effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-8
24. Blank MA, Gibson GW, Myers WR et al. Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 2000; 14: 1215-23
25. Nguyen DM, Schwartz J, Richardson P et al. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010; 55: 3404-7
26. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012; 18: 3524-31
27. Santini D, Schiavon G, Angeletti S et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: A new role for these drugs? Recent Pat Anticancer Drug Discov 2006; 1: 383-96
28. Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002; 14: 609-15
29. Morgan RO, Petersen LA, Hasche JC et al. VHA pharmacy use in veterans with Medicare drug coverage. Am J Manag Care 2009; 15: E1 - 8
30. Cramer JA, Gold DT, Silverman SL et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-31